Back to News Page
Emily Mirro, Co-Founder & President of SynchNeuro, discusses how brain-based technology is enabling a proactive, personalized approach to cardiometabolic health and early intervention.
10 leaders across the Boomerang Ventures portfolio are building companies that are redefining connected health. From digital therapeutics and musculoskeletal care to AI-driven metabolic monitoring and respiratory wellness, these innovators are tackling some of healthcare’s most complex challenges while developing scalable, data-driven solutions. This introductory feature highlights the leaders behind these companies and sets the stage for an upcoming series of individual Q&A profiles exploring their vision, leadership, and impact.
Source: Startup Health
SynchNeuro has secured seed-stage support from Boomerang Ventures to advance its brain-based, non-invasive continuous glucose monitoring technology. Using EEG-derived signals decoded by machine learning, the company is developing a wearable “Cardiometabolic Advisor” that tracks blood glucose and metabolic indicators without needles. The investment accelerates development and moves the device closer to broad market adoption.
Source: CityBiz
SynchNeuro, a Philadelphia-based health-technology startup founded by neurosurgeon Dr. Casey Halpern, has secured seed funding from Boomerang Ventures. The company is developing a non-invasive EEG-based platform that decodes brain-signal activity into metabolic insights, aiming to support individuals with prediabetes and early-stage Type 2 diabetes. The investment will help expand operations and accelerate product development.
Source: Indianapolis Business Journal
Boomerang Ventures has taken the lead in a $3 million seed round for SynchNeuro Inc., a Philadelphia-based health tech startup developing a wearable sensor that translates brainwave activity into real-time health insights. As part of the investment, Boomerang Founder and Managing Partner Oscar Moralez has joined the company’s board, strengthening the partnership as SynchNeuro advances its technology to monitor blood sugar and other critical health metrics.
Source: Tech Point
Boomerang Ventures is backing SynchNeuro’s pioneering effort to build the world’s first brain-based, non-invasive continuous glucose monitor. Using EEG-derived brainwave signals decoded by machine learning, SynchNeuro aims to track blood glucose and cardiometabolic indicators via a discreet wearable placed behind the ear. This seed-stage investment will help speed development of the “Cardiometabolic Advisor” system and bring proactive, needle-free monitoring closer to mass market.
Source: Business Insider
Boomerang Ventures has announced a seed-stage investment in SynchNeuro, a Philadelphia-based startup developing a brain-based, non-invasive wearable sensor to monitor blood glucose and other vital health metrics in real time. The firm’s backing supports SynchNeuro’s mission to use EEG-derived data and machine learning for proactive, needle-free cardiometabolic health insights.
Source: Morningstar
Boomerang Ventures has added SynchNeuro, Inc. to its seed-stage portfolio, investing to accelerate development of the world’s first brain-based, non-invasive continuous glucose monitor. The Indianapolis-based fund is backing the startup’s EEG-driven platform that decodes brainwave signals behind the ear to monitor glucose, sleep, stress and cardiometabolic health in real time. “The brain is the richest data source imaginable,” says SynchNeuro founder Dr. Casey Halpern.
Boomerang Ventures has announced a seed-stage investment in SynchNeuro, a pioneering neurotechnology company developing the world’s first brain-based, non-invasive continuous glucose monitor. The partnership accelerates SynchNeuro’s mission to revolutionize cardiometabolic health through EEG-based technology that interprets brain signals to track blood glucose and other vital metrics in real time. This innovative approach aims to make proactive, pain-free, and affordable glucose monitoring accessible to millions.
Back to News Page
